Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Hulstaert

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Clinical Microbiology|March 7, 2002
Evaluation of INNO-LIA syphilis assay as a confirmatory test for syphilisHans-Jochen Hagedorn, Anna Kraminer-Hagedorn, Katrien De Bosschere, et al.
Vaccine|August 7, 2004
A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteersGeert Leroux-Roels, Erik Depla, Frank Hulstaert, et al.
Trials|February 3, 2026
Good clinical trial funding practices: how can public funders reduce the risk of trial failure and improve health impact?Frank Hulstaert, Jillian Harrison, Hilde Nevens, et al.
International Journal of Technology Assessment in Health Care|January 10, 2013
Should chronic hepatitis B be treated as early as possible?Frank Hulstaert, Christoph Schwierz, Frederik Nevens, et al.
Human Vaccines|October 14, 2006
Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infectionGeert Leroux-Roels, Arsène-Hélène Batens, Isabelle Desombere, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 5, 2023
Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumabLeen Verleye, Diego Castanares-Zapatero, Carl Devos, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2023
Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indicationsMattias Neyt, Carl Devos, Nancy Thiry, et al.
International Journal of Dermatology|January 31, 2024
Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population-based study in BelgiumDiego Castanares-Zapatero, Leen Verleye, Carl Devos, et al.
AIDS (London, England)|June 12, 2003
Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptionsPhilippe Halfon, Jacques Durant, Philippe Clevenbergh, et al.
Journal of Clinical Microbiology|October 2, 2002
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assayAnna S F Lok, Fabien Zoulim, Stephen Locarnini, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Clinical Microbiology|March 7, 2002
Evaluation of INNO-LIA syphilis assay as a confirmatory test for syphilisHans-Jochen Hagedorn, Anna Kraminer-Hagedorn, Katrien De Bosschere, et al.
Vaccine|August 7, 2004
A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteersGeert Leroux-Roels, Erik Depla, Frank Hulstaert, et al.
Trials|February 3, 2026
Good clinical trial funding practices: how can public funders reduce the risk of trial failure and improve health impact?Frank Hulstaert, Jillian Harrison, Hilde Nevens, et al.
International Journal of Technology Assessment in Health Care|January 10, 2013
Should chronic hepatitis B be treated as early as possible?Frank Hulstaert, Christoph Schwierz, Frederik Nevens, et al.
Human Vaccines|October 14, 2006
Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infectionGeert Leroux-Roels, Arsène-Hélène Batens, Isabelle Desombere, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 5, 2023
Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumabLeen Verleye, Diego Castanares-Zapatero, Carl Devos, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2023
Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indicationsMattias Neyt, Carl Devos, Nancy Thiry, et al.
International Journal of Dermatology|January 31, 2024
Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population-based study in BelgiumDiego Castanares-Zapatero, Leen Verleye, Carl Devos, et al.
AIDS (London, England)|June 12, 2003
Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptionsPhilippe Halfon, Jacques Durant, Philippe Clevenbergh, et al.
Journal of Clinical Microbiology|October 2, 2002
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assayAnna S F Lok, Fabien Zoulim, Stephen Locarnini, et al.
Pageof 4